Publications

5491 Results

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Authors
Y Chae;E Dietrich;M Othus;L Il-Young Chung;H Kim;C Ryan;CD Blanke;S Patel;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 2514)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

SWOG S2107 - Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Authors
VK Morris;KA Guthrie;ES Kopetz;R Breakstone;T Karasic;I Hu;S Colby;M Fakih;S Gholami;PJ Gold;EG Chiorean;PA Philip
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3640)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer: Findings from the CALGB/SWOG 80405 (Alliance)

Authors
E Cheng;F Ou;C Ma;A Venook;H-J Lenz;E O'Reilly;P Campbell;C Kuang;B Caan;K Ng;J Meyerhardt
Journal / Conference
AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Sarcomatoid Lung Cohort #11

Authors
Y Chae;M Othus;S Patel;P Sandhu;L Corum;J Cetnar;S Rayani;L Il-Young Chung;M Chansky;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Biopsy analysis in S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

Authors
K Campbell;Z Bustami;D Chen;E Medini;J Maxey;C Gonzalez;N Naser Al Deen;I Baselga Carretero;A Vega-Crespo;J Ming Chen;L Kuklinski;K Kendra;B Chmielowski;T Truong;N Khushalani;F Collichio;A Ikeguchi;A Victor;K Margolin;J Sosman;S Patel;S Hu-Lieskovan;J Moon;S Bellasea;C Spencer;M Thompson;M Wu;A Vanderwalde;P Scumpia;A Ribas
Journal / Conference
AACR Annual Meeting (April 5-10, 2023, San Diego, CA), oral
Year
2024
Research Committee(s)
Melanoma
Study Number(s)
S1616

Expanding the Use of Artificial Intelligence while Protecting Data Privacy in Clinical Trials

Authors
C Cook;A Hoering;M LeBlanc
Journal / Conference
Society for Ciinical Trials (SCT) (May19-22, 2024, Boston, MA), oral
Year
2024
Research Committee(s)
Cancer Care Delivery

Decoding biomarkers of immune activation in neuroendocrine carcinomas treated with ipilimumab and nivolumab using a multiomic approach

Authors
C Haymaker;G Kumar;Y Chae;E Gonzalez-Koslova;C Dualt;J Zhang;M Othus;L Soto;G Manyam;P Jiang;E Cuentas;C Fernandez;A Reuben;H Maecker;S Gnjatic;G al-Atrash;J Zhang;J Lee;S Patel;R Kurzrock
Journal / Conference
ESMO Sarcoma and Rare Cancers Congress (March 14-16, 2024 Lugano, Switzerland), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A randomized trial of the addition of ruxolitinib to BCR::ABL1 tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) with molecular evidence of disease (SWOG trial S1712)

Authors
K Sweet;M Othus;S Tantravahi;J Radich;J Thompson;J Mendler;C Boddy;P Kumar;E Attalah;U Perepu;J Pinilla-Ibarz;A Moseley;H Erba
Journal / Conference
European Hematology Association Hybrid Congress (June 13-16, Madrid Spain) (EHA), oral
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
S1712

Randomized Phase II/III Study of R-CHOP +/- Venetoclax in Previously Untreated MYC/BCL2 Double Expressor Diffuse Large B Cell Lymphoma (DLBCL): Alliance A051701

Authors
J Abramson;S Geyer;L Pederson;S Giri;E Hsi;R Little;S Gore;D Landsburg;H Cherng;B Kahl;JW Friedberg;N Bartlett;J Leonard
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 7012)
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051701

Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)

Authors
J Grilley Olson;J Allred;S Schuetze;E Davis;A Poklepovic;M Wagner;R Riedel;A Hartranft;M Xu-Welliver;S Berg;S George;S Robinson;P Googe;S DAngelo;G Schwartz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 11514)
Year
2024